Theriva Biologics, Inc. (TOVX) is a clinical-stage biotechnology company traded on the NYSE American that develops oncolytic virus and microbiome-focused therapies for cancer and other high-unmet-need diseases. Its shares have been trading near historic lows, which makes the gap between the current price and the average analyst price target unusually wide. Here is a balanced look at what a $2.50 price target actually represents and what could drive — or derail — a move toward it.
The central target is calculated from two attributable, current targets. Maxim Group's Jason McCarthy set a $1.00 target and upgraded the stock to Buy from Hold on March 31, 2026. Alliance Global holds a Buy rating with a $4.00 target, lowered from $7.00 on March 13, 2026 following the company's fourth-quarter report. Averaging these two figures produces a mean of $2.50, within a wide $1 to $4 range.
Both firms are constructive, but their views diverge sharply on magnitude. The lower target reflects concern about Theriva's thin balance sheet and financing needs, while the higher target assigns greater value to the company's clinical pipeline. It is important not to treat this $2.50 average as a formal published consensus; it is simply the midpoint of two very different opinions about a small, high-risk biotechnology name.
Shares were trading near $0.16 in mid-November 2026, after closing at about $0.1542 the prior session, with a 52-week range of roughly $0.14 to $0.49. Reaching $2.50 would mean a move of more than 1,400%, which is a very large percentage change by any conventional standard. Because Theriva generates minimal revenue and posts losses, the path to a higher valuation depends far more on clinical data and financing than on current earnings.
A move of that magnitude would almost certainly require successful pivotal data, a licensing or partnership deal, or a substantial re-rating of the company's market capitalization, which currently sits near $7 million to $11 million. None of these outcomes is assured, and the share count has grown through multiple offerings, which dilutes the value of any clinical success for existing holders.
The stock's 52-week range of roughly $0.14 to $0.49 defines the current technical structure. The $0.14 area represents a key support level near the recent low, while $0.49 marks the prior 52-week high and a major resistance zone. In between, round-number levels such as $0.25, $0.50, and ultimately $1.00 would likely serve as psychological milestones on any sustained advance. Because the price sits below its longer-term moving averages, the prevailing trend remains downward, and any move toward $2.50 would need to first reclaim these intermediate levels.
Analyst price targets typically reflect a roughly 12-month research horizon, though the two firms here do not publish identical timeframes. The most relevant upcoming catalysts are quarterly financial results and guidance, updates on VIRAGE2 enrollment and VCN-01 data, financing announcements and dilution, analyst revisions, and any partnership or regulatory developments. Because Theriva is clinical-stage, trial data and capital-raising activity will likely matter more to the target than near-term revenue or EPS (earnings per share).
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced name like TOVX, such tools can help traders spot shifts in momentum and manage positions more efficiently. Traders can use these signals to discover new opportunities, monitor existing holdings, and identify changing trends. Explore the AI Daily Buy/Sell Signals to see how automated analysis can support your own research process.
The $2.50 figure is the midpoint of two credible but widely separated analyst targets — $1.00 from Maxim Group and $4.00 from Alliance Global — rather than a uniform market view. From a price near $0.16, the required gain exceeds 1,400%, an extremely demanding move that would depend on successful clinical execution, access to non-dilutive capital, and a major expansion of the company's valuation. The strongest supports are a de-risked pivotal path for VCN-01 and its early efficacy signal in pancreatic cancer, while dilution, cash burn, and binary trial risk are the principal obstacles. Investors should watch clinical data, financing terms, and analyst revisions rather than treat the $2.50 average as a likely near-term outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TOVX has been loosely correlated with GOVX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if TOVX jumps, then GOVX could also see price increases.
| Ticker / NAME | Correlation To TOVX | 1D Price Change % | ||
|---|---|---|---|---|
| TOVX | 100% | -7.00% | ||
| GOVX - TOVX | 54% Loosely correlated | -22.03% | ||
| GNPX - TOVX | 50% Loosely correlated | +1.46% | ||
| VOR - TOVX | 42% Loosely correlated | -2.10% | ||
| TVRD - TOVX | 41% Loosely correlated | N/A | ||
| QNRX - TOVX | 40% Loosely correlated | -2.43% | ||
More | ||||